- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04357353
The Role of Platelet Rich Plasma for Erectile Dysfunction
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Eligibility: Men with erectile dysfunction. Ages 50-80. International Index of Erectile Function score of mild (17-21/25) or moderate (8-16/25).
Intervention and Evaluation:Men who consent to join the trial will be randomized to receive either a single injection PRP or saline to the penis. All patients will have blood drawn in clinic the day of injection. Those randomized to PRP arm will have their own blood prepared and separated into the PRP. This solution of their own blood will be injected back into the penis.
Follow Up: Men will be evaluated at 1 , 3, and 6 months after the injections and then asked to complete the IIEF by phone or by electronic means
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Nebraska
-
Omaha, Nebraska, United States, 68198
- Unversity of Nebraska Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- history of mild to moderate erectile dysfunction measured by IIEF
Exclusion Criteria:
- history or prostate cancer treatment (prostatectomy, radiation, brachytherapy)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Sham Comparator: Placebo
All arms will have phlebotomy (blood drawn).
This group will receive saline injection only.
|
sham injection
Other Names:
|
Experimental: Platelet rich plasma
All arms will have phlebotomy (blood drawn).
This group will receive PRP injection only.
|
PRP will be used in the experimental arm.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Erectile Function Change
Time Frame: at 1, 3 and 6 months
|
The rate of change in erectile function measured by IIEF
|
at 1, 3 and 6 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Side Effects
Time Frame: at 1, 3 and 6 months
|
any side effects noted by men
|
at 1, 3 and 6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Chris Deibert, MD, MPH, University of Nebraska
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0156-20-FB
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Erectile Dysfunction
-
University of VirginiaActive, not recruitingErectile Dysfunction | Erectile Dysfunction Following Radical Prostatectomy | Erectile Dysfunction Following Radiation Therapy | Erectile Dysfunction Due to General Medical Condition | Erectile Dysfunction Due to Arterial InsufficiencyUnited States
-
Cairo UniversityRecruitingErectile Dysfunction | Erectile Dysfunction Following Radical Prostatectomy | Erectile Dysfunction Following Simple Prostatectomy | Erectile Dysfunction With Diabetes Mellitus | Erectile Dysfunction Due to Arterial Disease | Erectile Dysfunction Due to Injury | Erectile Dysfunction Due to Neuropathy and other conditionsEgypt
-
University of BaghdadCompletedSexual Dysfunction | Erectile Dysfunction | Erectile Dysfunction Following Radical Prostatectomy | Erectile Dysfunction Following Radiation Therapy | Sexual Abstinence | Erectile Dysfunction With Diabetes Mellitus | Sexual Desire Disorder | Erectile Dysfunction Following Cryotherapy | Erectile Dysfunction... and other conditionsIraq
-
BayerCompletedSexual Dysfunction | Male Erectile DysfunctionBelgium, Italy, France, Germany, Spain, Netherlands, South Africa
-
Cairo UniversityCompletedVasculogenic Erectile DysfunctionEgypt
-
InitiaTerminatedVasculogenic Erectile DysfunctionIsrael
-
InitiaCompletedVasculogenic Erectile DysfunctionIsrael
-
InitiaCompletedVasculogenic Erectile DysfunctionCzech Republic, Lithuania, Netherlands, Palestinian Territories, Occupied
-
Rexahn Pharmaceuticals, Inc.CompletedErectile Dysfunction (ED)United States
-
SK Chemicals Co., Ltd.TerminatedMale Erectile Dysfunction
Clinical Trials on Placebo Sham Injection
-
RepliCel Life Sciences, Inc.Syreon Corporation; Innovacell Biotechnologie AG; PHARMALOG Institut für klinische... and other collaboratorsCompletedIntrinsic Aging of Skin | Skin Wrinkling | Solar Degeneration of SkinGermany
-
The Jerzy Kukuczka Academy of Physical Education...Universitätsklinikum Hamburg-EppendorfCompleted
-
Wuhan Neurophth Biotechnology Limited CompanyRecruitingLeber's Hereditary Optic Neuropathy (LHON)China
-
Taipei Medical University WanFang HospitalUnknown
-
Taipei Medical University WanFang HospitalCompletedMyofascial Pain SyndromeTaiwan
-
Chengdu Kanghong Biotech Co., Ltd.CompletedCentral Retinal Vein Occlusion | Macular EdemaChina
-
Chengdu Kanghong Biotech Co., Ltd.UnknownDiabetic Macular EdemaChina
-
Quark PharmaceuticalsTerminatedNon Arteritic Anterior Ischemic Optic NeuropathyUnited States, Australia, Germany, China, India, Italy, Singapore, Israel
-
ThromboGenicsCompletedVitreomacular Adhesion Including Macular HoleUnited States
-
ThromboGenicsCompletedExudative Age-Related Macular Degeneration | Focal Vitreomacular AdhesionUnited States, United Kingdom, Germany, France, Belgium, Italy